drugset / Trial / NCT02075008
Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201
NaSingle-groupOpen-labelTreatment
Summary
This study planned to assess long-term safety of QGE031 during 12 months treatment in asthma patients who completed study CQGE031B2201.
Timeline
- Start
- 2014-03-27
- Primary completion
- 2016-03-22
- Completion
- 2016-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ligelizumab | Monoclonal antibody | 240 mg | Subcutaneous |